Advertisement
Advertisement

AZN

AZN logo

AstraZeneca PLC

166.71
USD
Sponsored
+0.73
+0.44%
Aug 24, 15:59 UTC -4
Closed
exchange

After-Market

165.34

-1.38
-0.82%

AstraZeneca PLC Profile

About

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

Info & Links

CEO

Pascal Soriot

Headquarters

1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS
CAMBRIDGE, X0 CB2 0AA, UNITED KINGDOM

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.astrazeneca.com

Auditor

PricewaterhouseCoopers LLP

Share holders

--

Employees

96,100

AstraZeneca PLC Statistics

Valuation Measures

Market Capitalization2

256.42B

Enterprise Value

281.01B

Enterprise Value/EBITDA(ttm)

13.83

Price to Earnings Ratio(ttm)

17.09

Price to Sales(ttm)

4.19

Price to Book(mrq)

5.11

Price to Cash(ytd)

12.84

Profitability

Gross Margin(ttm)

81.88%

Operating Margin(ttm)

24.66%

Profit Margin(ttm)

17.03%

Return on Equity(ttm)

31.45%

Return on Invested Capital(ttm)

14.43%

Return on Assets(ttm)

13.20%

Income Statement

Revenue(ttm)

61.37B

Revenue Per Share(ttm)

--

Gross Profit(ttm)

50.25B

EBITDA(ttm)3

20.33B

Net Income Available to Common(ttm)

10.45B

Diluted EPS(ttm)

6.69

Share Statistics

Beta (5Y Monthly)

0.26

52-Week Change

2.95%

S&P 500 52-Week Change

18.66%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

2.61%

Float4

0.00

% Held by Insiders

--

% Held by Institutions

20.35%

Balance Sheet

Total Cash(mrq)

5.04B

Total Cash Per Share(mrq)

--

Total Debt(mrq)

29.49B

Total Debt/Equity(mrq)

58.55%

Current Ratio(mrq)

0.89%

Quick Ratio(mrq)

0.67%

Book Value Per Share(mrq)

--

Cash Flow

Operating Cash Flow Per Share(ytd)

3.99

Free Cash Flow(ytd)

4.93B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement